文献速递内脏/肾动脉与血管畸形

达比加群酯对静脉畸形相关消耗性凝血病及疼痛有效

Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-10-31

本研究回顾性收集2019年9月至2021年6月19例静脉畸形合并局限性血管内凝血门诊患者,口服达比加群酯(成人110 mg每日两次,儿童55 mg每日两次)。全部19例凝血改善且疼痛缓解,16例可评估患者疼痛均改善,18/19例纤维蛋白原和D-二聚体改善,10/14例纤维蛋白降解产物改善;无病变消退或活动度改善,无出血事件。

要点

  • 19例静脉畸形合并局限性血管内凝血患者口服达比加群酯后凝血指标及疼痛均获益。
  • 16例可评估患者疼痛全部改善,18/19例纤维蛋白原和D-二聚体改善。
  • 无病变消退、外观改变或活动度改善,随访期间无出血事件。

核心结论

  • 达比加群酯治疗静脉畸形患者疼痛及局限性血管内凝血有效且安全。
  • 作者认为达比加群酯是术前改善静脉畸形患者凝血功能和疼痛的合适选择。

研究设计与样本

  • 回顾性收集2019年9月至2021年6月19例静脉畸形合并局限性血管内凝血门诊患者数据。
  • 患者口服达比加群酯,成人110 mg每日两次,儿童55 mg每日两次。
  • 治疗前后进行生物学血液检测、常规检查及凝血功能测定。

主要发现

  • 全部19例患者凝血改善且疼痛缓解;16例可评估患者疼痛均改善。
  • 18/19例患者纤维蛋白原和D-二聚体水平改善,10/14例纤维蛋白降解产物水平改善。
  • 无患者报告病变消退、外观改变或活动度改善。
  • 短期(<10天)与长期(≥10天)用药相比,D-二聚体、纤维蛋白原和纤维蛋白降解产物水平无显著差异。
  • 所有患者对达比加群酯耐受良好,随访期间无出血事件。

临床怎么用

  • 作者认为达比加群酯可作为术前改善静脉畸形患者凝血功能和疼痛的合适选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Consumptive coagulopathy treatment and pain management are crucial for patients with venous malformations (VMs). Dabigatran etexilate, a non-vitamin K antagonist oral anticoagulant, has known advantages compared with low-molecular-weight heparin and vitamin K antagonists, including oral administration, a more consistent pharmacokinetics/pharmacodynamics profile, a better safety profile, and no need for coagulation surveillance. In the present study, we tested the efficacy and safety of dabigatran etexilate for consumptive coagulopathy treatment and pain management for patients with VMs. METHODS: To investigate the efficacy and safety of dabigatran etexilate in treating localized intravascular coagulation (LIC) associated with VM, we retrospectively collected data for 19 outpatients with VM and LIC, who had been treated with dabigatran etexilate from September 2019 to June 2021. The patients provided oral informed consent and underwent biologic blood testing, routine examinations, and determination of coagulation function before and after treatment. The dosage of dabigatran etexilate was 110 mg twice daily for adults and 55 mg twice daily for children. RESULTS: All 19 patients had benefited from dabigatran etexilate treatment with coagulation improvement and pain relief. Pain had improved in all 16 evaluable patients. The fibrinogen and D-dimer levels had improved in 18 of 19 patients. The fibrin degradation product level had improved in 10 of 14 patients. None of patients reported lesion regression, appearance changes, or improvement in mobility. No significant differences were found in the D-dimer, fibrinogen, and fibrin degradation product levels between the short-term (<10 days) and long-term (≥10 days) use of the medication. Dabigatran etexilate was well tolerated by all patients. No bleeding event had occurred during follow-up. CONCLUSIONS: The results of our study have confirmed the efficacy and safety of dabigatran etexilate in treating pain and LIC in patients with VMs. Dabigatran etexilate is a suitable choice preoperatively to modify coagulation function and pain in patients with VMs.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Liu H, Hu L, Yang X, et al. Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 36328137. doi:10.1016/j.jvsv.2022.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。